Literature DB >> 22591358

Interleukin-7 biology in HIV disease and the path to immune reconstitution.

Scott F Sieg1.   

Abstract

Interleukin-7 (IL-7) is a cytokine that plays a critical role in T cell homeostasis by promoting proliferation and survival of mature T cells and also by enhancing thymic output for the generation of new T cells. IL-7 receptor expression and signaling function is perturbed in HIV infection and could contribute to disease pathogenesis. Even though highly active anti-retroviral therapy has markedly reduced morbidity and mortality in HIV-infected persons, there remains concern that a significant proportion of treated patients may experience relatively poor CD4+ T cell recovery despite sustained viral suppression. Recent human trials and animal studies suggest that IL-7 administration may provide a powerful tool to enhance T cell reconstitution in HIV-infected persons. The role of IL-7/IL-7 receptor perturbations in HIV pathogenesis and the potential to reconstitute immunity with IL-7 administration in the setting of HIV infection are important areas of investigation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22591358     DOI: 10.2174/157016212800792432

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  3 in total

Review 1.  Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature.

Authors:  Camilla Tincati; Esther Merlini; Antonella d'Arminio Monforte; Giulia Marchetti
Journal:  BMC Infect Dis       Date:  2018-01-05       Impact factor: 3.090

2.  Interleukin-7 facilitates HIV-1 transmission to cervico-vaginal tissue ex vivo.

Authors:  Andrea Introini; Christophe Vanpouille; Andrea Lisco; Jean-Charles Grivel; Leonid Margolis
Journal:  PLoS Pathog       Date:  2013-02-07       Impact factor: 6.823

3.  Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.

Authors:  Stefano Rusconi; Paola Vitiello; Fulvio Adorni; Elisa Colella; Emanuele Focà; Amedeo Capetti; Paola Meraviglia; Clara Abeli; Stefano Bonora; Marco D'Annunzio; Antonio Di Biagio; Massimo Di Pietro; Luca Butini; Giancarlo Orofino; Manuela Colafigli; Gabriella d'Ettorre; Daniela Francisci; Giustino Parruti; Alessandro Soria; Anna Rita Buonomini; Chiara Tommasi; Silvia Mosti; Francesca Bai; Silvia Di Nardo Stuppino; Manuela Morosi; Marco Montano; Pamela Tau; Esther Merlini; Giulia Marchetti
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.